Clinical Trials Logo

Radial Artery Occlusion clinical trials

View clinical trials related to Radial Artery Occlusion.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06293287 Recruiting - Clinical trials for Radial Artery Occlusion

Enoxaparin for Preventing the Radical Artery Occlusion After the Transradial Access Hepatic Arterial Infusion Chemotherapy

Start date: January 31, 2024
Phase: Phase 2
Study type: Interventional

The present investigation is designed as a single-blind, randomized, controlled, bicentric trial. The objective is to ascertain whether the subcutaneous administration of enoxaparin sodium for prophylactic anticoagulation during transradial hepatic arterial infusion chemotherapy (HAIC) can diminish the incidence of radial artery occlusion (RAO) post-procedure

NCT ID: NCT05591872 Recruiting - Clinical trials for Radial Artery Occlusion

Low Dose Heparin Factorial Trial

Start date: May 9, 2022
Phase: Phase 3
Study type: Interventional

An open label 2x2 factorial randomized trial is planned to determine the difference in mean hemostasis time between low dose heparin (LD) i.e between 2000-3000 IU and standard dose heparin (SD) i.e. 5000 IU with or without catecholamine chitosan-based pad (InnoSEAL hemostatic pad, InnoTherapy, Inc. S Korea) used in conjunction with TRB (InnoSEAL+TRB [I+TRB]) among patients who are undergoing left heart cath at Tabba Heart Institute. Secondary objectives include testing the difference in radial artery occlusion (RAO), and hematoma (III, IV grade) and composite outcome (RAO+hematoma).

NCT ID: NCT05399277 Recruiting - Clinical trials for Radial Artery Occlusion

Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion (CAPITAL-RAPTOR)

Start date: May 17, 2023
Phase: Phase 3
Study type: Interventional

Transradial access (TRA) is the preferred vascular access site for invasive coronary angiography. TRA is limited by blockage of the radial artery post-procedurally, preventing future use of TRA. This is referred to as radial artery occlusion (RAO) and occurs in ~5% of cases. While intraprocedural anticoagulation has been studied extensively to mitigate this complication, oral anticoagulation post-TRA has not. The investigators will assess the impact of a one-week course of rivaroxaban post-TRA to reduce the rate of ultrasound-defined RAO at 30 days.

NCT ID: NCT04933136 Recruiting - Clinical trials for Radial Artery Occlusion

Radial Artery Occlusion and Dual Artery Hemostasis After Transradial Approach.

Start date: December 12, 2022
Phase:
Study type: Observational [Patient Registry]

- Improving patient comfort and implementing the protocols required to minimize the risk of RAO must be part of quality control. - Several procedural parameters are related to the risk of RAO but hemostasis is a critical period. - Despite the fact that non-occlusive hemostasis of the radial artery is a recognized and effective technique for reducing the risk of RAO, it is rarely practiced because it is tedious, involves additional care and is not always effective with current hemostasis systems. - Prophylactic compression of the cubital artery during radial artery hemostasis has been shown to be effective in maintaining non-occlusive hemostasis but requires 2 devices and does not simplify care procedures. - The Terry2™ band is a new dual device that offers effortless non-occlusive radial hemostasis and does not require repeated intervention by nursing staff. The primary objectives of this observational study are to demonstrate the benefits, safety and impact on care of using Terry2™ band in patients undergoing diagnostic or interventional catheterization by radial (or ulnar) approach.

NCT ID: NCT04861389 Recruiting - Clinical trials for Radial Artery Occlusion

Distal Transradial Access for Primary Percutaneous Coronary Intervention in STEMI Patients

RESERVE
Start date: January 1, 2021
Phase: N/A
Study type: Interventional

The transradial access (TRA) is currently the preferred approach for percutaneous coronary intervention (PCI). However, in patients with ACUTE ST-segment elevation myocardial infarction (STEMI) after emergency PCI, the high incidence of THE radial artery RAO limits the future choice of the radial artery for percutaneous intervention. The literature reported that distal transradial access (dTRA) significantly reduced RAO after elective PCI, but the application of dTRA in emergency PCI in STEMI has not been reported. We have completed 126 cases of dTRA undergoing emergency PCI after STEMI, which has been preliminarily confirmed to be safe and effective. A single-center, open, prospective, randomized controlled study is planned to compare the use of dTRA and TRA in emergency PCI in STEMI patients. The primary endpoint was the INCIDENCE of RAO within 24 hours after surgery. This clinical study verified that dTRA compared with TRA could reduce the RAO incidence of STEMI patients after emergency PCI. The project will explore a new artery approach to reduce RAO, and provide a basis for the selection of artery approach in STEMI emergency PCI patients.

NCT ID: NCT04561648 Recruiting - Clinical trials for Radial Artery Occlusion

Standard vs High Dose of Unfractionated Heparin in the Incidence of Radial Artery Occlusion (DEFINITION) Trial.

DEFINITION
Start date: August 1, 2020
Phase: N/A
Study type: Interventional

Double blind single center clinical trial to compare the incidence of radial artery occlusion (RAO) using standard doses of Unfractionated Heparin (UFH) vs. high doses of UFH.

NCT ID: NCT03630055 Recruiting - Clinical trials for Radial Artery Occlusion

Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion

CAPITAL-RAPTOR
Start date: October 3, 2018
Phase: Phase 3
Study type: Interventional

Coronary angiography is performed to evaluate for obstructive coronary artery disease. This is commonly performed via the transfemoral or transradial approach with the latter increasing in frequency. One of the most common complications of transradial access is radial artery occlusion occurring in ~5% of patients which prohibits the use of the radial artery in the future. There is evidence to support the use of intraprocedural anticoagulation to mitigate the risk of radial artery occlusion however the role of post-procedural anticoagulation has not been previously evaluated. Rivaroxaban is a direct oral anticoagulant (DOAC) with a safety profile superior to that of vitamin K antagonists. Given the safety profile, ease of use, and feasibility of DOAC therapy, our study will endeavor to evaluate the use of rivaroxaban 15mg orally once daily for 7 days after transradial access and the impact this has on the rate of radial artery occlusion.